Anzen Industries Secures $2.2M Funding In Pre-Seed Round

Founded by scientists Amy Locks and Pedro Lovatt Garcia, Anzen Industries is a biomanufacturing company developing high-value chemicals using cell-free enzyme systems.

Anzen Industries develops reusable, low-infrastructure enzyme reactors that produce complex molecules more efficiently than traditional chemical synthesis, plant extraction, or fermentation methods.

The company aims to enhance the resilience, scalability and economic viability of global supply chains for critical chemicals across industries.

Read Also - Sinpex Secures €10M Series A To Grow AI-Powered KYB Platform Across Europe

Its platform combines proprietary enzyme reactor technology, enzyme immobilization techniques, and AI-driven design to carry out biochemical reactions outside living cells. This first-principles approach enables highly specific, tunable enzymes to operate in small, modular reactors allowing flexible, cost-effective scaling while reducing dependence on capital-intensive infrastructure.

Co-founder and CTO Pedro Lovatt Garcia outlined the company’s technical vision, saying: We started Anzen Industries because we believe that, from first principles, the future of manufacturing will be cell-free. If enzymes can be kept robust outside of the cell, we can carry out the same manufacturing reactions at a fraction of the infrastructure, energy and cost.

Traditional methods for producing complex chemicals face major constraints: organic synthesis is hard to scale, plant extraction relies on unpredictable agricultural supply and fermentation demands costly infrastructure and processing. Anzen’s cell-free system overcomes these challenges, boosting efficiency and reducing time to market.

Commenting on the investment, Julia Hawkins, General Partner at LocalGlobe, said Anzen is rethinking how critical molecules are produced from first principles, to improve speed, resilience, and control across global supply chains.

CEO and co-founder Amy Locks highlighted the role of Europe’s scientific ecosystem in the company’s early development, noting: Europe’s strong scientific heritage and innovation community allowed us to take our breakthrough from scientific discovery to a viable commercial venture.

The funding will support the relocation of operations to the U.S., the establishment of its first manufacturing facility, and the expansion of industrial collaborations and partnerships to grow its biomanufacturing platform.